CymaBay Therapeutics, Inc. — Operating Income by Fiscal Year
12 fiscal years, as filed with the SEC; every row links its evidence fact.
Cite as: FACTANKER, https://factanker.com/entity/7952cb80-c75f-4d7f-a480-d1fc37e358d5/serie/operating-income
| Fiscal year | Operating Income | Period | Evidence |
|---|---|---|---|
| FY 2023 | $-101.7M | 2023-01-01 – 2023-12-31 | evidence 0001193125-24-050758 |
| FY 2022 | $-93.1M | 2022-01-01 – 2022-12-31 | evidence 0001193125-23-077859 |
| FY 2021 | $-87.6M | 2021-01-01 – 2021-12-31 | evidence 0001193125-22-078287 |
| FY 2020 | $-52.6M | 2020-01-01 – 2020-12-31 | evidence 0001193125-21-094424 |
| FY 2019 | $-108.2M | 2019-01-01 – 2019-12-31 | evidence 0001193125-20-074946 |
| FY 2018 | $-72.5M | 2018-01-01 – 2018-12-31 | evidence 0001564590-19-005435 |
| FY 2017 | $-21.3M | 2017-01-01 – 2017-12-31 | evidence 0001564590-18-005831 |
| FY 2016 | $-25.6M | 2016-01-01 – 2016-12-31 | evidence 0001193125-17-093759 |
| FY 2015 | $-25.9M | 2015-01-01 – 2015-12-31 | evidence 0001193125-16-521392 |
| FY 2014 | $-24.0M | 2014-01-01 – 2014-12-31 | evidence 0001193125-15-101933 |
| FY 2013 | $-9.4M | 2013-01-01 – 2013-12-31 | evidence 0001193125-14-124127 |
| FY 2012 | $-10.4M | 2012-01-01 – 2012-12-31 | evidence 0001193125-14-124127 |
Methodology & sources
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).
CymaBay Therapeutics, Inc. — all facts · Revenue · Net Income